Brez internetne povezave — prikazana je shranjena različica strani.

Anavex Life Scien…

USUSD
← Na Filter Delnic

Anavex Life Sciences Corp (US:AVXL) — Biotechnology: Biological Products (No Diagnostic Substances). Število borz, na katerih se trgujejo delnice družbe: 2. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.

O Podjetju

Spletna Stran
anavex.com
Odnosi z Vlagatelji
anavex.com/investors/
Sektor
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Sedež
NEW YORK, United States
Izvršni Direktor
Terrie Kellmeyer
Zaposleni
34
Delnice v Obtoku
92.7 mio. na dan 2026-08-28
Prosto Prenosljive Delnice
89.81 mio.
Tržna Kapitalizacija
138.12 mio. USD
Notranje Osebe
1.71%
Institucionalni Vlagatelji
40.49%
Panoga (SIC)
Biological Products, (No Diagnostic Substances)
P/E
izguba
FCF
—
Dolg
345 USD
Dobiček in FCF — za 12 mesecev do 30.06.2026 (najnovejše poročilo podjetja).
Opis

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

oglas

Borze in Oznake

BorzaOznakaValutaCenaVrsta
US USA StocksAVXL glavnaUSD1.48 -1.99%navadne delnice
LSE London Stock Exchange0HFR IOBUSD2.1491 +0.00%navadne delnice

Cena v 3 Mesecih

dan rasti dan padcaPremaknite miško / tapnite dan — otvoritvena, zaključna, najvišja in najnižja cena

Največji Imetniki

ImetnikDeležDelniceDatum Poročila
Blackrock Inc.8.69%8.06 mio.2026-06-30
Vanguard Capital Managem…4.37%4.05 mio.2026-06-30
Two Sigma Investments, L…3.29%3.05 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…3.16%2.93 mio.2026-06-30
Geode Capital Management…2.6%2.41 mio.2026-06-30
iShares Trust-iShares Ru…2.57%2.38 mio.2026-08-31
Federated Hermes MDT Ser…2.21%2.05 mio.2026-07-31
State Street Corporation2.07%1.92 mio.2026-06-30
MISSLING CHRISTOPHER U (…≈1.63%1.51 mio.2025-09-11
Federated Hermes, Inc.1.16%1.07 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…1.12%1.04 mio.2026-06-30
Fidelity Salem Street Tr…1.08%1 mio.2026-07-31
AQR Capital Management,…1.04%963 0142026-06-30
Vanguard Portfolio Manag…1.02%948 6332026-06-30
Summit Financial, LLC0.98%909 4302026-06-30
Goldman Sachs Group Inc0.96%890 6342026-06-30
iShares Trust-iShares Ru…0.79%729 5922026-08-31
iShares Trust-iShares Bi…0.72%667 4422026-08-31
VANGUARD SCOTTSDALE FUND…0.49%450 2822026-05-31
SCHWAB STRATEGIC TRUST-S…0.47%440 2092026-05-31
iShares Trust-iShares Mi…0.34%312 6102026-08-31
THOMAS STEFFEN PHD (Dire…≈0.05%43 6512025-06-05